AZTherapies Overview
Founded
2011
Status
Private
Employees
12
Latest Deal Type
Series C
Latest Deal Amount
$30.9M
Investors
6
AZTherapies General Information
Description
Developer of pharmaceutical drugs designed to provide treatment for multiple neurodegeneration and neuroinflammation-related CNS diseases. The company's products include ALZT-OP1 is a novel multi-action combination drug regimen which is use to modify disease progression by slowing down or halting Alzheimer's disease early in its development, enabling healthcare providers to cure Alzheimer's patients.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 200 Clarendon Street
- 17th Floor
- Boston, MA 02116
- United States
AZTherapies Timeline
AZTherapies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 31-Jan-2020 | $30.9M | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series B) | 16-Oct-2018 | 000.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC | 0000 | 000.00 | Completed | Generating Revenue | ||
| 2. Later Stage VC (Series A) | 06-Feb-2017 | $16.4M | $26.4M | 00000 | Completed | Generating Revenue |
| 1. Early Stage VC | 06-Jan-2015 | $10M | $10M | Completed | Generating Revenue |
AZTherapies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A-2 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 0.000 | |
| Series A-1 | 2,084,052 | $0.000100 | $3.33 | $3.33 | 1x | $3.33 | 4.58% | |
| Series A | 4,212,559 | $0.000100 | $4 | $4 | 1x | $4 | 9.26% |
AZTherapies Competitors (39)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ALSP | Venture Capital-Backed | San Diego, CA | 00 | 00.000 | 0000000000 0 | |
| 000000000 00000000 | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 00000000 000000000 | Venture Capital-Backed | Boston, MA | 00 | 000.00 | 000000000000 | 000.00 |
| 000 000000 | Venture Capital-Backed | Cambridge, MA | 0 | 000.00 | 0000000000 0 | 000.00 |
| 000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 0 | 000.00 | 00000000000 | 000.00 |
AZTherapies Executive Team (9)
1 Former Executive
AZTherapies Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Elmaleh Ph.D | AZTherapies | Founder, Chairman & Chief Executive Officer | 000 0000 |
| David Taft | Self | Board Member | 000 0000 |
| George Behrakis | AZTherapies | Board Member | 000 0000 |
| Gillian Sandler | Self | Board Member | 000 0000 |
| John Porter | AZTherapies | Board Member | 000 0000 |
AZTherapies Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Cosine (NYC biotech investors) | Other | Minority | 000 0000 | 000000 0 | |
| DRADS Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | |
| IBS Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Spinnaker Capital Group | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Wexford Capital | Asset Manager | Minority | 000 0000 | 000000 0 |
AZTherapies Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 000000000000 | 24-Oct-2019 | 000000000000000000 | Biotechnology | 00000 0000000 00.0 |
Ready to get started?
Request a free trial